secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001104659-23-089299
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio Q2 2023 revenue $14.5M (+39% YoY); reaffirms FY23 guidance $60-65M
---------------------------------------------------------------------------

- Q2 revenue $14.5M, up 39% YoY; H1 revenue $26.4M, up 42% YoY.
- Gross margin improved to 70% vs 63% in Q2 2022 due to better inventory management.
- Net loss $10.8M, narrower than $12.7M loss in prior-year quarter.
- FY2023 revenue guidance reaffirmed: $60-65M, representing 45-57% growth.
- Cash $65.3M after underwritten public offering netting ~$46.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465923089299/0001104659-23-089299-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465923089299/tm2323228d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-089299

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer